Drug Trial Radar · NCT06930885
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
7,713
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
May 2031
Study completion May 2031
Sponsor
- Lead sponsor
- Hospital do CoracaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.
Conditions
- Atherothrombotic Diseases
- Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)Drug
Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin 1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg or 2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg or 3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg or 4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg or 5. Valsartan 80 mg + Atorvastatin 40 mg + Aspirin 100 mg or 6. Valsartan 80 mg + Atorvastatin 80 mg + Aspirin 100 mg or 7. Valsartan 80 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 8. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 9. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\* * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)
Colchicine 0.5 mgDrug
Colchicine 0.5 mg once daily
Usual Care GroupDrug
Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.
Colchicine-placebo 0.5 mgDrug
Matching Colchicine-placebo 0.5 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary efficacy endpoint: Major adverse cardiovascular and limb events (MACLE)Time frame: Through study completion, an estimated average of 3 years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Centro de Pesquisas Clínicas Dr. Marco Mota
Maceió, Alabama, Brazil · Recruiting
Secretária da Saúde do Estado do Ceará - Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Messejana, Ceará, Brazil · Recruiting
Empresa Brasileira de Serviços Hospitalares - EBSERCH - Hospital de Ensino Dr. Washington Antônio de Barros- HU-UNIVASF
Petrolina, Pernambuco, Brazil · Recruiting
Centro de Pesquisa Cardiolima
Teresina, Piauí, Brazil · Recruiting
Fundação Técnico Educacional Souza Marques
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Fundação Universitária de Cardiologia - ICFUC
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Instituto de Pesquisa e Ensino em Saúde - IPES
Porto Velho, Rondônia, Brazil · Recruiting
CMEP - Centro Multidisciplinar de Ensino especializado e Pesquisa
Joinville, Santa Catarina, Brazil · Recruiting
Hospital Universitário São Francisco na Providência de Deus
Bragança Paulista, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina São José do Rio Preto
São José do Rio Preto, São Paulo, Brazil · Recruiting
CIPES - Centro Internacional de Pesquisa Clínica
São José dos Campos, São Paulo, Brazil · Recruiting
Hcor
São Paulo, São Paulo, Brazil · Recruiting
Centro de Pesquisa Cetrus
São Paulo, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.